CellgramⓇ is the brand name of the Pharmicell’s stem cell drug.

Since its establishment in 2002, Pharmicell has devoted to developing stem cell drugs to benefit more people with desperate needs and successfully developed the world’s first stem cell drug on July 1st, 2011, marking a new era in the world history of cell treatment. The path for innovation and challenge pioneered by Pharmicell to become the world first, has set Korean Standards in the area of stem cell drugs and has changed the spectrum of the overseas stem cell industry beyond the boundary of Korea. In addition, Pharmicell has emerged as the global leader of biopharmaceutical raw materials development and is recognized for its technology with our exporting performance of raw medicine to prominent global pharmaceutical companies. Moreover, Pharmicell strives further to develop the next generation of new drugs based on the management value of fusion and challenge. Pharmicell will take the lead for Korea to become the outstanding leader of biopharmaceutical industries of the world through continuous R&D and ultimately create value for a healthy and happy human life.

‘Cellgram-AMI’ is the world first stem cell drug approved by the Ministry of Foods and Drug Safety of Korea in July 2011. The name of the item at the time of approval was HearticellgramⓇ-AMI’. It is manufactured using autologous bone marrow-derived mesenchymal stem cell. It is an effective and efficient method to improve the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty within 72 hours after expression of chest pain.